FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

20.09.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for ...

Related Keywords

United States ,Canada , ,Twitter ,European Network For Gynaecological Oncology Trial ,Foundation Inc ,Exchange Commission ,Linkedin ,Facebook ,Merck Co Inc ,Youtube ,Instagram ,Statement Of Merck Co Inc ,Combined Positive Score ,European Network ,Gynaecological Oncology Trial ,Among Merck ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Patients With Multiple ,Neck Squamous Cell ,Bacillus Calmette Guerin Unresponsive ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Looking Statement ,Litigation Reform Act ,Annual Report ,Merck Co Chart ,Erck Co Kurs ,Erck Co Aktie ,